Early Signals at ASCO 2026 | Can TIL Therapy Reach More Patients?
Can the next generation of TIL therapies overcome the barriers that have limited broader adoption of cell therapy in solid tumors?
In this episode of Early Signals, Wael Harb, MD, sits down with Parameswaran Hari, MD, Chief Medical Officer at Obsidian Therapeutics, to discuss how engineered tumor-infiltrating lymphocyte (TIL) therapies are evolving beyond first-generation approaches. Drawing on his experience leading the clinical development of lifileucel and now advancing OBX-115, Dr. Hari explores how controllable cytokine expression, streamlined manufacturing and patient-centric trial design may help make cell therapies safer, more accessible and easier to deliver across a broader range of treatment centers.
Together, they examine preliminary clinical data from an ongoing study of OBX-115, an investigational therapy that has not been approved by regulatory authorities. The conversation also explores where TIL therapy fits within an increasingly complex immuno-oncology landscape and why continued innovation in manufacturing, accessibility and global drug development will be essential to bringing these therapies to more patients.
In this episode, you'll learn:
- Why next-generation TIL therapies are being engineered to improve safety, scalability and patient access.
- How OBX-115 uses a pharmacologically regulated IL-15 "switch" to modulate T-cell activity after infusion.
- What early ASCO 2026 clinical data suggest about efficacy, durability and safety in checkpoint inhibitor-resistant melanoma.
- How innovations in manufacturing and trial design may expand the future role of cell therapy across solid tumors.
- Why Dr. Hari believes accessibility, affordability and global collaboration will define the next era of oncology drug development.
Related Content
Looking for exclusive insight?
